¡°	COC user	10.785128633938466
¡°	various COC preparation	7.219989846841723
¡°	early coc	6.651361173105528
¡°	COC suppress production	5.396395084782637
	John Guillebaud	4.583929258426028
	seven placebo pill	4.564864635105345
	four placebo pill	4.548105893381245
¡°	low dose COC formulation	4.457592463958156
¡°	COC product	4.302055342931965
	birth control pill	4.287808142141585
	forget pill	4.169537342221142
¡°	low dose coc	3.5119706019144394
¡°	high dose coc	3.5110622077702107
	folliculogenesis	3.3450595764881963
	monthly pill pack	3.2542641528929948
	mg DRSP	3.1210367839434467
	EE dosage	3.0649038547042995
	unregulated pill free interval	2.6650352798591346
	ovarian follicle	2.4500466185803726
	twenty four active pill	2.4271199751307995
	twenty one active pill	2.4269354730469184
	unintended pregnancy	2.4262264669677736
	weak ovarian suppression	2.4227154067959638
	pill free week	2.421706882418961
	reduce pill free interval	2.3867656368127323
	ovarian activity	2.230962542167169
	Landgren	2.0896313355952203
	D.Nev February	2.086721615144733
	D.Nev March	2.085346234297953
	D.Nev April	2.085041241820864
	natural ovarian cycle	2.0313030228903464
¡°	low dose extend regimen coc	1.8969345849367822
	dose regimen	1.8823580828974253
	synthetic progestin drospirenone	1.794408217160694
	synthetic hormone exposure	1.7866427485334142
	synthetic hormone concentration	1.748561626065646
	synthetic estrogen exposure	1.6915888692493048
	follicular maturation	1.6872604636339346
	hormone dose	1.6820203180873676
	Nevada	1.674182486739137
	Molloy	1.6725297882440981
	escape ovulation	1.6668094261934976
	contraceptive efficacy	1.6576128296112145
¡°	combined oral contraceptive	1.6400627280134452
	contraceptive effect	1.6033243759032845
	estrogen dose	1.5869664388032583
	inhibitory synthetic hormone	1.5143646986918358
	natural hormone	1.4749443623073413
	market YAZ	1.2569385767155192
	sustain follicular suppression	1.1507748021311877
	menstrual cycle	1.000694287235383
	North Dakota Goldstuck et al Use	1.0000483143655472
	ethinylestradiol	0.9657127237536643
	hormone direct process	0.8609031210097987
	thromboembolism	0.8375052351499174
	Alameda	0.8375052351499174
	fiction	0.8375052351499174
	Hormonal Consequences	0.8375052351499174
¡°	low dose extend regimen combine oral contraceptive	0.7809034301336822
	immature oocyte	0.7190925500069406
	fertile oocyte	0.7190925500069406
	natural menstrual bleeding	0.683249155197776
	three Consecutive Artificial Cycles	0.6281378302219744
¡°	first COCs	0.5580609024529498
	bloating	0.48309516328168445
	E. Diczfalusy	0.42318548054870214
	nausea	0.33676159783459947
	Huber	0.33676159783459947
	Cnty	0.33676159783459947
	seven day placebo period	0.2819513497130594
	withdrawal bleed	0.21992316328839331
	Partial Final Judgment	0.21022421757222384
	oral contraception	0.17203769523764365
	relatively high daily dos	0.1707228114338768
	patent.1	0.16656161624449084
	daily administration	0.14894659269466684
	deleterious side effect	0.11333857311060551
	Sandoz	0.10671969610948154
	dosage unit	0.1065565585196615
	intake error	0.08507158270191834
	misuse	0.07970319120507166
	paramount importance	0.07078150082437439
	anda	0.06998734299140835
	European Patent Application Publication	0.06537563948124461
	acceptance	0.06335747845925477
	another strategy	0.06024228252964581
	Paragraph IV certification	0.05953534220402096
	regular break	0.051704621909264885
	combination preparation	0.050103593727562686
	continued presence	0.04723581811227223
	approximate length	0.04101529554623683
	Ninth Circuit	0.03796410533771255
	Abbreviated New Drug Applications	0.03404804214716961
	Summary judgment	0.029911324842920865
	consolidated infringement action	0.027965559101823405
	Civil Case	0.02637270163387291
	pharmaceutical formulation	0.025735204781255648
	FDA	0.02254592105730278
	ANDA filing	0.020814884610220363
	First two day	0.01819526051804022
	nonmove party	0.014176979173911213
	undesirable side effect	0.01403749879834216
	final approval	0.01358791262504276
	Teva Pharm. Indus	0.013431857905781068
	generic pharmaceutical manufacturer	0.01269016792667498
	Lourie	0.010623857877066519
	approximately first two week	0.010319903193833527
	introduction	0.009582577242197948
	last day	0.006896648018294398
	U.S. Food Drug Administration	0.006473620111170469
	five four day	0.006365666126866239
	four five day	0.006365666126866239
	competitor counterclaim	0.006042509345352433
	market generic version	0.005634709073642152
	Obviousness	0.004598194429419862
	WL	0.003207529874790928
	December	0.0027879661533993013
	regional circuit law	0.0026885741206450846
	Teleflex Inc.	0.0026581476568579877
	Med	0.0025460979889731943
	June	0.0022869561705978333
	potential side effect	0.0020743647451537204
	numerous prior art reference	0.0019261496338451151
	deference	0.001618951197140137
	R.Civ	0.0012630596936982483
	sole issue	0.0012183288234487888
	denial	0.0009387953326671552
	six prior art reference	0.0008240682774173665
	genuine dispute	0.0008031896625568226
	genuine issue	0.00080098178537906
	district court entry	0.0006585235642295368
	sale	0.0005439173639651629
	combination product	0.00024163100315228534
	addition	0.00021948653382202428
	final judgment	0.00020164735633693088
	summary judgment ruling	0.0001961146401049882
	jurisdiction	0.00017006296328339553
	underlie issue	9.243446731332911e-05
	background	8.035765824535939e-05
	obviousness issue	7.815126325853268e-05
	favor	6.839016978330925e-05
	invalidity	6.382358403396305e-05
	example	4.256365709021568e-05
	view	4.056899689491088e-05
	order	1.5450261972291675e-05
	U.S.C.	8.841783538518377e-06
	patentee	3.984222849541403e-06
	time	3.675229333384603e-06
	material fact	3.1955606539574105e-06
	cite prior art	2.6616057918617713e-06
	assert	1.9213398035011528e-06
	light	1.3800499118256865e-06
	first application	9.662660384003438e-07
	district court grant	4.842943687492738e-07
	present prior art	1.0471790582670228e-07
	District	0.0
	Court	0.0
	Appeals	0.0
	United States	0.0
	Fed	0.0
